|4-(3-((3-甲基苄基)氧基)亚苄基)-1-苯基吡唑烷-3,5-二酮|CsnPharm

CAS No.: 429653-73-6

Y16 Catalog No. CSN18268

Synonyms: Y16

Y16 is an inhibitor of G-protein–coupled Rho GEFs and works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Y16 is an inhibitor of G-protein–coupled Rho GEFs and works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00289757	Hepatitis A	Phase 4	Completed	-	Belgium ... more >> GSK Investigational Site Wilrijk, Belgium, 2610 Collapse <<
NCT02661100	Non Small Cell Lung Cancer ... more >> Advanced Triple Negative Breast Cancer Small Cell Lung Cancer Urothelial Cancer Mesothelioma Malignant Melanoma Collapse <<	Phase 1 Phase 2	Withdrawn(Drug unavailable)	July 2018	-
NCT00289757	-	-	Completed	-	-

更多
参考文献

[1] Zhang SM, Li WG, et al. Purification and characterization of a low-temperature hydroxylamine oxidase from heterotrophic nitrifier Acinetobacter sp. Y16. Biomed Environ Sci. 2014 Jul;27(7):515-22.
[2] Shang X, Marchioni F, et al. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3155-60.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.6013 mL
- 13.0064 mL
- 26.0127 mL
- 5 mM
- 0.5203 mL
- 2.6013 mL
- 5.2025 mL
- 10 mM
- 0.2601 mL
- 1.3006 mL
- 2.6013 mL

技术信息

CAS号	429653-73-6	储存条件	粉末 Sealed in dry,2-8°C 液体 -20°C:3-6 月 -80°C:12月
分子式	C24H20N2O3	运输	蓝冰
分子量	384.43	别名	Y16

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT00289757	Hepatitis A	Phase 4	Completed	-	Belgium ... more >> GSK Investigational Site Wilrijk, Belgium, 2610 Collapse <<
NCT02661100	Non Small Cell Lung Cancer ... more >> Advanced Triple Negative Breast Cancer Small Cell Lung Cancer Urothelial Cancer Mesothelioma Malignant Melanoma Collapse <<	Phase 1 Phase 2	Withdrawn(Drug unavailable)	July 2018	-
NCT00289757	-	-	Completed	-	-
NCT02978586	Prostate-specific Membrane Ant... more >>igen Positive Tumors Prostate Cancer Breast Cancer Lung Cancer Collapse <<	Not Applicable	Recruiting	September 2020	United States, Ohio ... more >> Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44106-5065 Contact: Norbert Avril 216-286-3210 Norbert.Avril@UHhospitals.org Principal Investigator: Norbert Avril Collapse <<
NCT02986048	-	-	Recruiting	December 2027	United States, Ohio ... more >> University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44106 Contact: David B Mansur, MD 216-844-2517 david.mansur@UHhospitals.org Principal Investigator: David B Mansur, MD Collapse <<

Y16 Catalog No. CSN18268

靶点选择性

请登录您的专属账户

确认信息